2-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-5-(1H-pyrazol-5-yl)-1,3,4-thiadiazole
C21H16F2N8S — CID 121395057
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-5-(1H-pyrazol-5-yl)-1,3,4-thiadiazole
2-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-5-(1H-pyrazol-5-yl)-1,3,4-thiadiazole (PubChem CID 121395057) has the molecular formula C21H16F2N8S and a molecular weight of 450.48 g/mol. Its IUPAC name is 2-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-5-(1H-pyrazol-5-yl)-1,3,4-thiadiazole.
Molecular Properties
| Compound Name | 2-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-5-(1H-pyrazol-5-yl)-1,3,4-thiadiazole |
|---|---|
| PubChem CID | 121395057 |
| Molecular Formula | C21H16F2N8S |
| Molecular Weight | 450.48 g/mol |
| Exact Mass | 450.12 |
| IUPAC Name | 2-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-5-(1H-pyrazol-5-yl)-1,3,4-thiadiazole |
| SMILES | Fc1ccc(F)c(C2CCCN2c2ccn3ncc(-c4nnc(-c5ccn[nH]5)s4)c3n2)c1 |
| InChI | InChI=1S/C21H16F2N8S/c22-12-3-4-15(23)13(10-12)17-2-1-8-30(17)18-6-9-31-19(26-18)14(11-25-31)20-28-29-21(32-20)16-5-7-24-27-16/h3-7,9-11,17H,1-2,8H2,(H,24,27) |
| InChIKey | VSQBBUDCWNETNS-UHFFFAOYSA-N |
| XLogP | 4.26 |
| TPSA | 87.89 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 450.48 |
| LogP ≤ 5 | 4.26 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 121395057 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.